Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,268
Total Claims
$11.8M
Drug Cost
876
Beneficiaries
$14K
Cost/Patient
Risk Score Breakdown 7/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,101 Rheumatology providers
-71%
Opioid rate vs peers
1.2% vs 4.1% avg
+124%
Cost per patient vs peers
$14K vs $6,039 avg
+158%
Brand preference vs peers
19.6% vs 7.6% avg
Opioid Prescribing
1.2%
Opioid Rate
109
Opioid Claims
$998
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,793 claims · $11.6M
Generic: 7,370 claims · $231K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Adalimumab | 481 | $4.3M |
| Etanercept | 292 | $2.2M |
| Tofacitinib Citrate | 197 | $1.2M |
| Upadacitinib | 128 | $819K |
| Immune Globul G/Gly/Iga Avg 46 | 20 | $776K |
| Abatacept | 104 | $659K |
| Belimumab | 84 | $285K |
| Abatacept/Maltose | 45 | $228K |
| Tofacitinib Citrate | 25 | $145K |
| Sarilumab | 27 | $111K |
| Denosumab | 64 | $107K |
| Adalimumab | 14 | $104K |
| Hydroxychloroquine Sulfate | 1,434 | $87K |
| Etanercept | 12 | $85K |
| Infliximab-Dyyb | 21 | $81K |
Prescribing Profile
Patient Profile
69
Avg Age
81%
Female
1.76
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About